Merck KGaA - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: /s/ Christian Uhrich, Authorized signatory of Merck KGaA, Darnstadt, Germany
Issuer symbol: XLO
Transactions as of: 21 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 21 Oct 2021, 20:50:57 UTC
Next filing: 26 Oct 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XLO	Series B Preferred Stock							21 Oct 2021	Common Stock	416,060		See footnote	F1, F2
holding	XLO	Series C Preferred Stock							21 Oct 2021	Common Stock	264,765		See footnote	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F2	The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
F3	The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.